Philippe Moreau
YOU?
Author Swipe
View article: Figure S1 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
Figure S1 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel Open
Consort Diagram
View article: Table S4 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
Table S4 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel Open
HR and P values for landmark PFS within first year
View article: Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network Open
The treatment landscape of heavily pretreated relapsed/refractory MM has changed considerably in recent years with the introduction of novel BCMA‐ and GPRC5D‐directed immunotherapies, including CAR T‐cell therapy, bispecific antibodies (Bs…
View article: 35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience Open
Frontline high-dose therapy (HDT) is, in 2025, the standard of care for patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT). Prior to high-dose melphalan, induction therapy with quadruplet c…
View article: Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone Open
Circulating tumor cells (CTC) represent a high-risk biomarker in newly diagnosed multiple myeloma (NDMM); however, their prognostic value among transplant-eligible (TE) patients receiving daratumumab with bortezomib/lenalidomide/dexamethas…
View article: Enhanced Brain‐Heart Connectivity as a Precursor of Reduced State Anxiety after Therapeutic Virtual Reality Immersion (Adv. Sci. 38/2025)
Enhanced Brain‐Heart Connectivity as a Precursor of Reduced State Anxiety after Therapeutic Virtual Reality Immersion (Adv. Sci. 38/2025) Open
View article: European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma
European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma Open
Given the evolving understanding of genetic risk factors in multiple myeloma (MM), this paper assesses whether next‐generation sequencing (NGS) could complement or even replace fluorescence in situ hybridization (FISH) at diagnosis. A stru…
View article: Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial Open
View article: Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study Open
Idecabtagene vicleucel (ide-cel), an adoptive chimeric antigen receptor (CAR) T-cell therapy directed against B-cell maturation antigen (BCMA), has demonstrated high response rates and improved survival in patients with relapsed/refractory…
View article: Enhanced Brain‐Heart Connectivity as a Precursor of Reduced State Anxiety after Therapeutic Virtual Reality Immersion
Enhanced Brain‐Heart Connectivity as a Precursor of Reduced State Anxiety after Therapeutic Virtual Reality Immersion Open
State anxiety involves transient feelings of tension and nervousness in response to threats, which can escalate into anxiety disorders if persistent. Despite treatments, 30%–50% of individuals show limited improvement, and neurophysiologic…
View article: A Patient-Centered Education Through Massive Open Online Course (MOOC) for Multiple Myeloma Patient and Caregivers: A Descriptive Study of Knowledge Gains by AF3M and IFM (Preprint)
A Patient-Centered Education Through Massive Open Online Course (MOOC) for Multiple Myeloma Patient and Caregivers: A Descriptive Study of Knowledge Gains by AF3M and IFM (Preprint) Open
View article: Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma
Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma Open
What is this summary about? This plain language summary describes the results of the first study on subcutaneous (under the skin) injection of a medicine called isatuximab for people with multiple myeloma. Multiple myeloma is a type of blo…
View article: Talquetamab improves patient‐reported symptoms and health‐related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL‐1 study
Talquetamab improves patient‐reported symptoms and health‐related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL‐1 study Open
Background Talquetamab is the first approved G protein–coupled receptor family C group 5 member D–targeting bispecific antibody for the treatment of triple‐class exposed relapsed/refractory multiple myeloma (RRMM) on the basis of results f…
View article: EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma Open
View article: Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma Open
The treatment of newly diagnosed multiple myeloma (NDMM) has advanced rapidly in recent years, with the standard of care (SOC) now including not only triplet combinations of proteasome inhibitors (PIs), immunomodulatory agents, and steroid…
View article: Distribution reappraisal of peripheral T‐ and NK‐cell lymphoma entities through the French Lymphopath network database
Distribution reappraisal of peripheral T‐ and NK‐cell lymphoma entities through the French Lymphopath network database Open
International audience
View article: Data from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Data from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential Open
Purpose:We designed mathematical models to describe and quantify the mechanisms and dynamics of minimal residual disease (MRD) in order to better understand these MRD dynamics; inform future treatment design, including when to stop or chan…
View article: Figure 6 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Figure 6 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential Open
Model validation from the MAIA trial: PFS predictions from original data compared with actual results from updated data. CI, confidence interval. Kaplan–Meier curves are shown with censoring ticks removed.
View article: Figure 4 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Figure 4 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential Open
Time to achievement of CR or better by arm in patients achieving CR or better.
View article: Figure 2 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Figure 2 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential Open
Y-intercept versus log doubling time (days). CR, complete response; MRD-ve, minimal residual disease-negative.
View article: Supplementary Data 1 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Supplementary Data 1 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential Open
supplementary online material, tables, figures, mathematics.
View article: Figure 1 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Figure 1 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential Open
Example curves showing back-extrapolation of Y-intercepts and estimated growth rates from sequential MRD values. DT, doubling time; r, correlation coefficient. Note: Example results are shown for four individual patients. Green dashed line…
View article: Figure 5 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Figure 5 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential Open
Overall PFS model fits to DRd and Rd arms, combining response subgroups. Kaplan–Meier curves are shown with censoring ticks removed.
View article: Figure 3 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Figure 3 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential Open
Minimum time spent below the LOD (months) by whether values increased above the LOD again or not. aLOD group 3, values go below the LOD and stay below the LOD (≥2 values below the LOD). bLOD group 4, values at or belo…
View article: Lésion métastatique du talus mimant une monoarthrite
Lésion métastatique du talus mimant une monoarthrite Open
View article: Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment : diagnostic and prognostic impact
Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment : diagnostic and prognostic impact Open
The co-primary aims of this study were to assess the diagnostic and prognostic performance of Whole-body-2-[18F]-fluorodeoxyglucose-positron emission tomography coupled with MRI (WB-2-[18F]FDG-PET/MRI) imaging in the …
View article: Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential Open
Purpose: We designed mathematical models to describe and quantify the mechanisms and dynamics of minimal residual disease (MRD) in order to better understand these MRD dynamics; inform future treatment design, including when to stop or cha…
View article: Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplantineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial
Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplantineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial Open
Patients with multiple myeloma meeting frailty criteria have worse outcomes than those identified as non-frail. Here, we present a post-hoc subgroup analysis of IMROZ, a global, phase III, open-label study investigating isatuximab (Isa) wi…
View article: Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti‐<scp>CD38</scp> Antibodies: The <scp>EMMY</scp> Cohort From 2017 to 2020
Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti‐<span>CD38</span> Antibodies: The <span>EMMY</span> Cohort From 2017 to 2020 Open
Aims/Background Recent agents have profoundly reshaped the multiple myeloma (MM) landscape. Their real‐world impacts need to be assessed over the long term. Methods EMMY is a non‐interventional, prospective dynamic cohort, conducted in Fra…
View article: Correction to: Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carflzomib and antiCD38 monoclonal antibodies
Correction to: Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carflzomib and antiCD38 monoclonal antibodies Open
International audience